PharmaTher (PHRRF) Holdings announced the U.S. Food and Drug Administration has approved the Company’s ketamine product, herein referred to as KETARx, on August 8th, 2025, for its indicated uses in surgical pain management. This FDA approval signifies a momentous achievement for PharmaTher and strategically positions the Company to contribute to the psychedelic pharmaceutical revolution by leveraging its commercial and clinical initiatives with ketamine towards mental health, neurological, and pain disorders.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHRRF:
- Psychedelic: atai Life Sciences, Beckley Psytech report BPL-003 study results
- PharmaTher Sets Path for Ketamine Commercialization with FDA Approval Goal
- PharmaTher sees path to ketamine commercialization with no planned financing
- PharmaTher Secures U.S. Patent for Ketamine in ALS, Strengthening Market Position
- PharmaTher secures U.S. patent for ketamine in ALS